^
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
DVD Sensitive: B - Late Trials
|
DVD Sensitive: B - Late Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
Isa-KRd Sensitive: C2 – Inclusion Criteria
|
Isa-KRd Sensitive: C2 – Inclusion Criteria
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials
|
Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
bortezomib Resistant: C3 – Early Trials
|
bortezomib Resistant: C3 – Early Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
midostaurin Sensitive: D – Preclinical
|
midostaurin Sensitive: D – Preclinical
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
PFI-3 Sensitive: D – Preclinical
|
PFI-3 Sensitive: D – Preclinical
|
